Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: RETRACTED ARTICLE: Exosome-mediated lncRNA AFAP1-AS1 promotes trastuzumab resistance through binding with AUF1 and activating ERBB2 translation

Fig. 3

High AFAP1-AS1 level was associated with poor response to breast cancer patients receiving trastuzumab treatment. a AFAP1-AS1 was upregulated in trastuzumab-resistant patients compared to patients responding to trastuzumab treatment, * Pā€‰<ā€‰0.05. b Pearson correlation testing identified a significant positive association between tissue AFAP1-AS1 and serum AFAP1-AS1 expression. c Serum AFAP1-AS1 level was increased in trastuzumab-resistant patients than in trastuzumab-responding patients, * Pā€‰<ā€‰0.05. d The proportion of patients showing response to trastuzumab treatment was significant lower in high AFAP1-AS1 group than in low AFAP1-AS1 group. e Kaplan-Meier survival analysis showed that patients expressing high AFAP1-AS1 level had poorer overall survival and progressive-free survival

Back to article page